دورية أكاديمية
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
| العنوان: | Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project |
|---|---|
| المؤلفون: | Srdan Verstovsek, Ivan Krečak, Florian H. Heidel, Valerio De Stefano, Kenneth Bryan, Mike W. Zuurman, Michael Zaiac, Mara Morelli, Aoife Smyth, Santiago Redondo, Erwan Bigan, Michael Ruhl, Christoph Meier, Magali Beffy, Jean-Jacques Kiladjian |
| المصدر: | Biomedicines, Vol 11, Iss 7, p 1925 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Biology (General) |
| مصطلحات موضوعية: | polycythemia vera, thromboembolic events, machine learning, real-world evidence, hydroxyurea, ruxolitinib, Biology (General), QH301-705.5 |
| الوصف: | Patients with polycythemia vera (PV) are at significant risk of thromboembolic events (TE). The PV-AIM study used the Optum® de-identified Electronic Health Record dataset and machine learning to identify markers of TE in a real-world population. Data for 82,960 patients with PV were extracted: 3852 patients were treated with hydroxyurea (HU) only, while 130 patients were treated with HU and then changed to ruxolitinib (HU-ruxolitinib). For HU-alone patients, the annualized incidence rates (IR; per 100 patients) decreased from 8.7 (before HU) to 5.6 (during HU) but increased markedly to 10.5 (continuing HU). Whereas for HU-ruxolitinib patients, the IR decreased from 10.8 (before HU) to 8.4 (during HU) and was maintained at 8.3 (after switching to ruxolitinib). To better understand markers associated with TE risk, we built a machine-learning model for HU-alone patients and validated it using an independent dataset. The model identified lymphocyte percentage (LYP), neutrophil percentage (NEP), and red cell distribution width (RDW) as key markers of TE risk, and optimal thresholds for these markers were established, from which a decision tree was derived. Using these widely used laboratory markers, the decision tree could be used to identify patients at high risk for TE, facilitate treatment decisions, and optimize patient management. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2227-9059 |
| العلاقة: | https://www.mdpi.com/2227-9059/11/7/1925Test; https://doaj.org/toc/2227-9059Test |
| DOI: | 10.3390/biomedicines11071925 |
| الوصول الحر: | https://doaj.org/article/eb02741743d8467e933216cdd1bce442Test |
| رقم الانضمام: | edsdoj.b02741743d8467e933216cdd1bce442 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.b02741743d8467e933216cdd1bce442 969 3 Academic Journal academicJournal 969.127075195313 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.b02741743d8467e933216cdd1bce442&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/eb02741743d8467e933216cdd1bce442 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=22279059&ISBN=&volume=11&issue=7&date=20230701&spage=1925&pages=1925-1925&title=Biomedicines&atitle=Identifying%20Patients%20with%20Polycythemia%20Vera%20at%20Risk%20of%20Thrombosis%20after%20Hydroxyurea%20Initiation%3A%20The%20Polycythemia%20Vera%E2%80%94Advanced%20Integrated%20Models%20%28PV-AIM%29%20Project&id=DOI:10.3390/biomedicines11071925 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Srdan+Verstovsek%22">Srdan Verstovsek</searchLink><br /><searchLink fieldCode="AR" term="%22Ivan+Krečak%22">Ivan Krečak</searchLink><br /><searchLink fieldCode="AR" term="%22Florian+H%2E+Heidel%22">Florian H. Heidel</searchLink><br /><searchLink fieldCode="AR" term="%22Valerio+De+Stefano%22">Valerio De Stefano</searchLink><br /><searchLink fieldCode="AR" term="%22Kenneth+Bryan%22">Kenneth Bryan</searchLink><br /><searchLink fieldCode="AR" term="%22Mike+W%2E+Zuurman%22">Mike W. Zuurman</searchLink><br /><searchLink fieldCode="AR" term="%22Michael+Zaiac%22">Michael Zaiac</searchLink><br /><searchLink fieldCode="AR" term="%22Mara+Morelli%22">Mara Morelli</searchLink><br /><searchLink fieldCode="AR" term="%22Aoife+Smyth%22">Aoife Smyth</searchLink><br /><searchLink fieldCode="AR" term="%22Santiago+Redondo%22">Santiago Redondo</searchLink><br /><searchLink fieldCode="AR" term="%22Erwan+Bigan%22">Erwan Bigan</searchLink><br /><searchLink fieldCode="AR" term="%22Michael+Ruhl%22">Michael Ruhl</searchLink><br /><searchLink fieldCode="AR" term="%22Christoph+Meier%22">Christoph Meier</searchLink><br /><searchLink fieldCode="AR" term="%22Magali+Beffy%22">Magali Beffy</searchLink><br /><searchLink fieldCode="AR" term="%22Jean-Jacques+Kiladjian%22">Jean-Jacques Kiladjian</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Biomedicines, Vol 11, Iss 7, p 1925 (2023) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => MDPI AG, 2023. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Biology (General) ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22polycythemia+vera%22">polycythemia vera</searchLink><br /><searchLink fieldCode="DE" term="%22thromboembolic+events%22">thromboembolic events</searchLink><br /><searchLink fieldCode="DE" term="%22machine+learning%22">machine learning</searchLink><br /><searchLink fieldCode="DE" term="%22real-world+evidence%22">real-world evidence</searchLink><br /><searchLink fieldCode="DE" term="%22hydroxyurea%22">hydroxyurea</searchLink><br /><searchLink fieldCode="DE" term="%22ruxolitinib%22">ruxolitinib</searchLink><br /><searchLink fieldCode="DE" term="%22Biology+%28General%29%22">Biology (General)</searchLink><br /><searchLink fieldCode="DE" term="%22QH301-705%2E5%22">QH301-705.5</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Patients with polycythemia vera (PV) are at significant risk of thromboembolic events (TE). The PV-AIM study used the Optum® de-identified Electronic Health Record dataset and machine learning to identify markers of TE in a real-world population. Data for 82,960 patients with PV were extracted: 3852 patients were treated with hydroxyurea (HU) only, while 130 patients were treated with HU and then changed to ruxolitinib (HU-ruxolitinib). For HU-alone patients, the annualized incidence rates (IR; per 100 patients) decreased from 8.7 (before HU) to 5.6 (during HU) but increased markedly to 10.5 (continuing HU). Whereas for HU-ruxolitinib patients, the IR decreased from 10.8 (before HU) to 8.4 (during HU) and was maintained at 8.3 (after switching to ruxolitinib). To better understand markers associated with TE risk, we built a machine-learning model for HU-alone patients and validated it using an independent dataset. The model identified lymphocyte percentage (LYP), neutrophil percentage (NEP), and red cell distribution width (RDW) as key markers of TE risk, and optimal thresholds for these markers were established, from which a decision tree was derived. Using these widely used laboratory markers, the decision tree could be used to identify patients at high risk for TE, facilitate treatment decisions, and optimize patient management. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2227-9059 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.mdpi.com/2227-9059/11/7/1925; https://doaj.org/toc/2227-9059 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3390/biomedicines11071925 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/eb02741743d8467e933216cdd1bce442" linkWindow="_blank">https://doaj.org/article/eb02741743d8467e933216cdd1bce442</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.b02741743d8467e933216cdd1bce442 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/biomedicines11071925
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 1
[StartPage] => 1925
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => polycythemia vera
[Type] => general
)
[1] => Array
(
[SubjectFull] => thromboembolic events
[Type] => general
)
[2] => Array
(
[SubjectFull] => machine learning
[Type] => general
)
[3] => Array
(
[SubjectFull] => real-world evidence
[Type] => general
)
[4] => Array
(
[SubjectFull] => hydroxyurea
[Type] => general
)
[5] => Array
(
[SubjectFull] => ruxolitinib
[Type] => general
)
[6] => Array
(
[SubjectFull] => Biology (General)
[Type] => general
)
[7] => Array
(
[SubjectFull] => QH301-705.5
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Srdan Verstovsek
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ivan Krečak
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Florian H. Heidel
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Valerio De Stefano
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kenneth Bryan
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mike W. Zuurman
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Michael Zaiac
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mara Morelli
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aoife Smyth
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Santiago Redondo
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Erwan Bigan
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Michael Ruhl
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Christoph Meier
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Magali Beffy
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jean-Jacques Kiladjian
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 07
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 22279059
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 11
)
[1] => Array
(
[Type] => issue
[Value] => 7
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Biomedicines
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |